Page 82 - 2019_05-HaematologicaMondo-web

E. Lombardi et al.
61. De Franceschi L, Franco RS, Bertoldi M, et al.
Pharmacological inhibition of calpain-1 pre- vents red cell dehydration and reduces Gardos channel activity in a mouse model of sickle cell disease. FASEB J. 2013;27(2):750- 759.
62. Stocker JW, De Franceschi L, McNaughton- Smith GA, et al. ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice. Blood. 2003;101(6):2412-2418.
63. de Franceschi L, Baron A, Scarpa A, et al. Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation. Blood. 2003;102(3):1087-1096.
64. Saggu G, Cortes C, Emch HN, et al. Identification of a novel mode of comple- ment activation on stimulated platelets mediated by properdin and C3(H2O). J Immunol. 2013;190(12):6457-6467.
65. Atkinson C, Zhu H, Qiao F, et al. Complement-dependent P-selectin expres- sion and injury following ischemic stroke. J Immunol. 2006;177(10):7266-7274.
66. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429-439.
67. Slomski A. Crizanlizumab prevents sickle cell pain crises. JAMA. 2017;317(8):798.
68. Telen MJ, Wun T, McCavit TL, et al.
Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood. 2015;125(17):2656-2664.
69. Harder MJ, Anliker M, Hochsmann B, et al. Comparative analysis of novel complement- targetedinhibitors, miniFH, and the natural regulators factor H and factor H-like protein 1 reveal functional determinants of comple- ment regulation. J Immunol. 2016;196(2): 866-876.
70. Nichols EM, Barbour TD, Pappworth IY, et al. An extended mini-complement factor H molecule ameliorates experimental C3 glomerulopathy. Kidney Int. 2015;88(6): 1314-1322.
928
haematologica | 2019; 104(5)